References
- Muder RR, Harris AP, Muller S, Edmond M, Chow JW, Papadakis K, et al. Bacteraemia caused by Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicentre study of 91 episodes. Clin Infect Dis 1996; 22: 508–12
- Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998; 11: 57–80
- Vartivarian SE, Papadakis KA, Palacios JA, Manning JT, Jr, Anaissie EJ. Mucocutaneous and soft tissue infections caused by Xanthomonas maltophilia: a new spectrum. Ann Intern Med 1994; 121: 969–73
- Jaber S, Chanques G, Matecki S, Ramonatxo M, Vergne C, Souche B, et al. Post-extubation stridor in intensive care unit patients. Risk factors evaluation and importance of the cuff-leak test. Intensive Care Med 2003; 29: 69–74
- Laing FP, Ramotar K, Read RR, Alfieri N, Kureishi A, Henderson EA, Louie TJ. Molecular epidemiology of Xanthomonas maltophilia colonization and infection in the hospital environment. J Clin Microbiol 1995; 33: 513–8
- Schaumann R, Stein K, Eckhardt C, Ackermann G, Rodloff AC. Infections caused by Stenotrophomonas maltophilia: a prospective study. Infection 2001; 29: 205–8
- Sakhnini E, Weissmann A, Oren I. Fulminant Stenotrophomonas maltophilia soft tissue infection in immunocompromized patients: an outbreak transmitted via tap water. Am J Med Sci 2002; 323: 269–72
- Weiss K, Restieri C, De Carolis E, Laverdiere M, Guay H. Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 2000; 45: 363–5
- Bonfiglio G, Cascone C, Azzarelli C, Cafiso V, Marchetti F, Stefani S. Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates. J Antimicrob Chemother 2000; 45: 115–7
- Betriu C, Sanchez A, Palau ML, Gomez M, Picazo JJ. Antibiotic resistance surveillance of Stenotrophomonas maltophilia, 1993–1999. J Antimicrob Chemother 2001; 48: 152–4
- Gesu GP, Marchetti F, Piccoli L, Cavallero A. Levofloxacin and ciprofloxacin in vitro activities against 4003 clinical bacterial isolates collected in 24 Italian laboratories. Antimicrob Agents Chemother 2003; 47: 816–9
- Lanzafame A, Bonfiglio G, Santini L, Mattina R. In vitro activity of levofloxacin against recent Gram-negative nosocomial pathogens. Chemotherapy 2005; 51: 44–50
- Bellmann R, Kuchling G, Dehghanyar P, Zeitlinger M, Minar E, Mayer BX, et al. Tissue pharmacokinetics of levofloxacin in human soft tissue infections. Br J Clin Pharmacol 2004; 57: 563–8